Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Myrexis Inc. Clear all
Not listed Phase 1Phase 2 Interventional

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

NCT00635557
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
MPC-6827 + Carboplatin
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Sep 30, 2026, 1:12 AM EDT
Terminated Phase 3 Interventional

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

NCT00380276
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MPC-7869
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
84
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Sep 30, 2026, 1:12 AM EDT
Completed No phase listed Observational

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

NCT00478686
View directory record Official record
Conditions
Breast Cancer
Interventions
Phlebotomy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 30, 2026, 1:12 AM EDT
Not listed Phase 2 Interventional

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

NCT00045123
View directory record Official record
Conditions
Prostate Cancer
Interventions
tarenflurbil, adjuvant therapy
Drug · Procedure
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
58
States / cities
Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

NCT00609011
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MPC-6827 + Temozolomide
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Ocoee, Florida • Greenville, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Sep 30, 2026, 1:12 AM EDT
Terminated Phase 2 Interventional

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
View directory record Official record
Conditions
HIV Infections
Interventions
MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*

NCT00511368
View directory record Official record
Conditions
HIV Infections
Interventions
matching placebo, Bevirimat
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

NCT00892931
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Azixa
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2011 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

NCT01097070
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Bevirimat
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • Fort Lauderdale, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 1 Interventional

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

NCT00920205
View directory record Official record
Conditions
Cancer
Interventions
MPC-3100 (an Hsp90 inhibitor)
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2011 · Synced Sep 30, 2026, 1:12 AM EDT
Active, not recruiting Not applicable Interventional

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

NCT04396808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score)
Device · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
8
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 3 Interventional

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00105547
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
MPC-7869
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
132
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 5, 2009 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 1 Interventional

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

NCT00393965
View directory record Official record
Conditions
Brain Neoplasms
Interventions
MPC-6827
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2008 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 1 Interventional

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

NCT00394446
View directory record Official record
Conditions
Refractory Solid Tumors
Interventions
MPC-6827
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 13, 2008 · Synced Sep 30, 2026, 1:12 AM EDT
Terminated Phase 3 Interventional

Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00322036
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
MPC-7869
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
55 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Sep 30, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

NCT01285414
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Verubulin, Temozolomide & Radiation Therapy
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Stanford, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Sep 30, 2026, 1:12 AM EDT